Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE: 002399)
China
· Delayed Price · Currency is CNY 9.84
0.00 (0.00%)
Sep 9, 2024, 1:35 PM CST
Shenzhen Hepalink Pharmaceutical Group Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -242.92 | -783.26 | 727.43 | 240.79 | 1,024 | 1,059 | Upgrade
|
| Depreciation & Amortization | 350.75 | 356.98 | 307.66 | 302.74 | 303.99 | 255.59 | Upgrade
|
| Other Amortization | 35.31 | 27.69 | 10.54 | 4.64 | 3.48 | 3.76 | Upgrade
|
| Loss (Gain) From Sale of Assets | 2.64 | 1.6 | 2.76 | 5.1 | -0.38 | -2.65 | Upgrade
|
| Asset Writedown & Restructuring Costs | 113.23 | 113.37 | 0.42 | 1.1 | 0.24 | 48.46 | Upgrade
|
| Loss (Gain) From Sale of Investments | -119.79 | 391.48 | 175.2 | 226.82 | -761.59 | -732.46 | Upgrade
|
| Provision & Write-off of Bad Debts | -11.5 | 0.71 | 48.86 | 71.85 | 10.59 | - | Upgrade
|
| Other Operating Activities | 1,034 | 1,090 | 283.59 | 267.7 | 318.73 | 255.36 | Upgrade
|
| Change in Accounts Receivable | -201.9 | 270.55 | -176.1 | 141.77 | -346.75 | -479.16 | Upgrade
|
| Change in Inventory | 1,445 | -619.67 | -2,152 | -1,520 | -763.88 | -744.39 | Upgrade
|
| Change in Accounts Payable | 2.19 | -213.93 | 59.71 | 423.9 | 172.52 | 94.34 | Upgrade
|
| Change in Other Net Operating Assets | - | - | -1.46 | -2.24 | -96.56 | -85.91 | Upgrade
|
| Operating Cash Flow | 2,236 | 398.22 | -756.61 | -6.63 | 37.28 | -227.6 | Upgrade
|
| Capital Expenditures | -396.42 | -444.88 | -222.42 | -193.86 | -212.49 | -362.08 | Upgrade
|
| Sale of Property, Plant & Equipment | 4.61 | 2.34 | 2.53 | 1.72 | 0.22 | 0.02 | Upgrade
|
| Divestitures | - | - | - | - | - | -75.9 | Upgrade
|
| Investment in Securities | 625.44 | 1,585 | 336.53 | 323.36 | -2,038 | 396.86 | Upgrade
|
| Other Investing Activities | 213.53 | 79.04 | 133.2 | 588.71 | 76.36 | 42.79 | Upgrade
|
| Investing Cash Flow | 447.15 | 1,222 | 249.84 | 719.93 | -2,174 | 1.7 | Upgrade
|
| Long-Term Debt Issued | - | 5,196 | 6,756 | 3,694 | 4,516 | 5,974 | Upgrade
|
| Long-Term Debt Repaid | - | -6,030 | -6,162 | -3,767 | -5,230 | -4,670 | Upgrade
|
| Net Debt Issued (Repaid) | -1,624 | -833.32 | 594.15 | -72.79 | -714.06 | 1,304 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 3,538 | - | Upgrade
|
| Common Dividends Paid | -370.95 | -425.89 | -251.01 | -412.48 | -447.48 | -342.51 | Upgrade
|
| Other Financing Activities | 62.41 | 49.04 | -13.58 | -15.81 | 129.72 | -1,196 | Upgrade
|
| Financing Cash Flow | -1,932 | -1,210 | 329.56 | -501.08 | 2,506 | -234.33 | Upgrade
|
| Foreign Exchange Rate Adjustments | 13.86 | 36.32 | 17.28 | -62.83 | -116.27 | 10.67 | Upgrade
|
| Net Cash Flow | 764.66 | 445.94 | -159.93 | 149.39 | 253.71 | -449.56 | Upgrade
|
| Free Cash Flow | 1,839 | -46.66 | -979.03 | -200.49 | -175.21 | -589.68 | Upgrade
|
| Free Cash Flow Margin | 33.02% | -0.86% | -13.67% | -3.15% | -3.29% | -12.75% | Upgrade
|
| Free Cash Flow Per Share | 1.25 | -0.03 | -0.67 | -0.14 | -0.13 | -0.47 | Upgrade
|
| Cash Income Tax Paid | 79.24 | -6.9 | -270.8 | -129.34 | 90.52 | -28.89 | Upgrade
|
| Levered Free Cash Flow | 1,614 | 57.09 | -1,494 | -435.43 | -254.76 | -1,968 | Upgrade
|
| Unlevered Free Cash Flow | 1,731 | 196.6 | -1,347 | -309.41 | -99.93 | -1,807 | Upgrade
|
| Change in Net Working Capital | -1,764 | -405.63 | 2,067 | 944.07 | 828.74 | 2,171 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.